Nicox S.A. (0RCQ.L)
| Previous close | 3.3200 |
| Open | 3.3243 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.3243 - 3.3243 |
| 52-week range | 3.3243 - 3.3243 |
| Volume | 216 |
| Avg. volume | N/A |
| Market cap | 96.255M |
| Beta (5Y monthly) | 1.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5370 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Nicox Provides Third Quarter 2021 Business and Financial Highlights
Press ReleaseNicox Provides Third Quarter 2021 Business and Financial Highlights VYZULTA® and ZERVIATE® prescriptions in the U.S. increased by 35% and 213% respectively in Q3 2021 compared to Q3 2020 Net Revenue of €2.4 million in the third quarter of 2021 and cash of €32.7 million on September 30, 2021 October 19, 2021– release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, provided business and financial highlights f
- Globe Newswire
Nicox to present at the OIS Glaucoma Virtual Innovation Showcase
FOR INFORMATIONNicox to present at the OIS Glaucoma Virtual Innovation ShowcaseOctober 13, 2021 Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, announced that Mr Michele GARUFI, Chairman and Chief Executive Officer of Nicox, will present at the Ophthalmology Innovation Summit (OIS) Glaucoma Innovation Showcase being held virtually on October 21, 2021. Nicox’s presentation will be focused on nitric oxide in glaucoma. The video webcast
- Globe Newswire
Nicox Launches New Corporate & Investor Website
Press ReleaseNicox Launches New Corporate & Investor WebsiteOctober 4, 2021 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the launch of its redesigned corporate and investor website.The new corporate website, www.nicox.com, features: New visual image for NicoxIntroductory video on the CompanyMechanism-of-action video on NCX 470, our lead product candidate in glaucomaNew layout and easier acce
